1. Home
  2. STSS vs IXHL Comparison

STSS vs IXHL Comparison

Compare STSS & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sharps Technology Inc.

STSS

Sharps Technology Inc.

HOLD

Current Price

$1.84

Market Cap

43.8M

Sector

Health Care

ML Signal

HOLD

Logo Incannex Healthcare Inc.

IXHL

Incannex Healthcare Inc.

HOLD

Current Price

$3.83

Market Cap

37.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
STSS
IXHL
Founded
2017
2001
Country
United States
Australia
Employees
55
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.8M
37.0M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
STSS
IXHL
Price
$1.84
$3.83
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
169.6K
249.3K
Earning Date
04-06-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$12,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.42
$0.16
52 Week High
$18.23
$6.39

Technical Indicators

Market Signals
Indicator
STSS
IXHL
Relative Strength Index (RSI) 48.87 55.48
Support Level $1.66 $0.33
Resistance Level $2.00 $5.08
Average True Range (ATR) 0.11 0.35
MACD -0.02 0.07
Stochastic Oscillator 25.00 74.14

Price Performance

Historical Comparison
STSS
IXHL

About STSS Sharps Technology Inc.

Sharps Technology Inc is a medical device and pharmaceutical packaging company offering patented, smart-safety syringe products to the healthcare industry. The Company's product lines focus on providing ultra-low waste capabilities that incorporate syringe technologies that use both passive and active safety features. The Company has adopted a digital asset treasury scheme focused on accumulating SOL, the native digital asset of the Solana blockchain, leveraging capital markets raises to power on-chain yield generation with the Solana Ecosystem.

About IXHL Incannex Healthcare Inc.

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Share on Social Networks: